Mizuho Maintains Outperform on Sarepta Therapeutics, Raises Price Target to $31

Benzinga Newsdesk www.benzinga.com Positive 92.5%

Neg 0% Neu 0% Pos 92.5%

Mizuho analyst Uy Ear maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Outperform and raises the price target from $26 to $31.